- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00989391
A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth
15. Dezember 2009 aktualisiert von: Pfizer
A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects
The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given once or twice daily by mouth for 10 days.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
36
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Singapore, Singapur, 188770
- Pfizer Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
21 Jahre bis 55 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Cohort 1
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Experimental: Cohort 2
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Experimental: Cohort 3
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
safety & toleration: Adverse events, vital signs, 12 lead ECG, blood and urine safety tests, suicidality assessment using the Suicidality Tracking Scale (STS) and physical examination.
Zeitfenster: 10 days
|
10 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Plasma pharmacokinetics: Cmax, Tmax, AUCtau, t½, AUCtau (Day 10)/AUCtau (Day 1), CL/F
Zeitfenster: 10 days
|
10 days
|
|
Urine pharmacokinetics: Ae24 & Ae24% (for once daily doses) or Ae12 & Ae12% (for twice daily dose) on Day 10, CLR
Zeitfenster: 10 days
|
10 days
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Oktober 2009
Primärer Abschluss (Tatsächlich)
1. Dezember 2009
Studienabschluss (Tatsächlich)
1. Dezember 2009
Studienanmeldedaten
Zuerst eingereicht
2. Oktober 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
2. Oktober 2009
Zuerst gepostet (Schätzen)
5. Oktober 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
16. Dezember 2009
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
15. Dezember 2009
Zuletzt verifiziert
1. Dezember 2009
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- B0711002
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .